Ozempic vs Wegovy: side-by-side comparison covering FDA status, mechanism, dosing, pricing, head-to-head trial data.
Both items are reviewed at GLP1 One Rx against the v3.0 transparency rubric and published clinical evidence.
Ozempic is FDA-approved for type 2 diabetes, while Wegovy is the semaglutide brand approved for chronic weight management and cardiovascular risk reduction. Both are made by Novo Nordisk with the same active ingredient.
Ozempic tops out at 2.0 mg weekly for type 2 diabetes, while Wegovy goes up to 2.4 mg weekly for weight management after stepping through 0.25, 0.5, 1.0 and 1.7 mg, about four weeks per step.
Through NovoCare, the Wegovy pen is $349 a month, with new patients paying $199 for the first two fills through December 31, 2026; the Wegovy pill is $149, $199 or $299 a month by dose (read October 14, 2026).
The Medicare GLP-1 Bridge runs July 1, 2026 to December 31, 2027 with a $50 copay for eligible Part D members on Wegovy, with prior authorization and BMI-based criteria. Open enrollment is October 15 to December 7, 2026.